Indian Covid-19 Vaccine: Union Health Minister Mansukh Mandaviya announced on Tuesday that the Central Drugs Standard Control Organization (CDSCO) has approved the COVID-19 vaccine from the Serum Institute of India Covovax, the jab of Biological E Corbevax and the anti-Covid pill Molnupiravir for restricted use in emergencies.
The Union Minister of Health announced via Twitter, saying: “To further strengthen the fight against COVID-19, the CDSCO and the Ministry of Health and Family Welfare have given 3 approvals in one single day. “
CDSCO’s COVID-19 Subject Matter Expert Committee (SEC) gave Covovax and Corbevax a nod on Monday under certain conditions. It also recommended granting restricted emergency use authorization for molnupiravir.
Six other Covid-19 vaccines – Covishield from Serum Institute, Covaxin from Bharat Biotech, ZyCoV-D from Zydus Cadila, Sputnik V from Russia, and Moderna and Johnson and Johnson from the US – had already received EUA from India’s more early.
CORBEVAX
Hyderabad-based company Biological-E will manufacture the Corbevax covid-19 vaccine. This is the first RBD protein subunit vaccine locally developed in India against the coronavirus. It is now the third vaccine against covid to be developed in India.
COVOVAX
The Pune-based Serum Institute of India will produce the nanoparticle vaccine, Covovax.
MOLNUPIRAVIR
The antiviral drug molnupiravir will now be manufactured in India by a consortium of 13 pharmaceutical companies. It will be of restricted use in emergency situations for the treatment of adult patients with coronavirus and those at high risk of disease progression.
<—-ALSO READ—->
Yellow Alert in Delhi: 10 p.m – 5 a.m night curfew under GRAP – Know what’s open, what’s closed
